Site augmentation emerges as a dynamic response to the growing complexity and volume of clinical trials, and the challenge of limited resources at clinical research sites. This support model, which is ...

This webinar features a panel with both clinical sites and industry representatives to discuss the support sites need to streamline operations and enhance patient experience. This webinar discussion ...

Arango today announced that PSI CRO, a global clinical research organization, has reduced clinical trial site identification from up to six weeks to minutes using SYNETIC™, an AI-enabled knowledge ...

In this podcast, clinical trial site representatives give pharma direct insight into what they view as the essential support mechanisms required to lessen the burden of clinical trials for both ...

MINNEAPOLIS--(BUSINESS WIRE)--NMDP BioTherapies announced today that CIBMTR CRO Services now offers a rapid clinical site selection and activation service, resulting in faster trial enrollment for ...

On Sept. 18, 2024, the U.S. Food & Drug Administration (FDA) issued a final guidance document titled “Conducting Clinical Trials With Decentralized Elements, Guidance for Industry, Investigators, and ...

Biodexa Pharmaceuticals PLC announced the activation of its first clinical study site for the Phase 3 Serenta trial, which aims to evaluate the efficacy and safety of eRapa in treating familial ...

Audit preparedness is essential for every clinical research site. By operationalizing compliance in your daily procedures, you can effectively mitigate risk and ensure smooth inspections. Start by ...

New sites expected to further accelerate patient enrollment, which surpassed 50% in Phase III study, as well as support future clinical programs GelrinC is set to transform cartilage repair market ...

FIRST SITE INITIATION VISIT COMPLETED IN AUSTRALIA SARASOTA, Fla., March 12, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company pioneering brain-tar ...

LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a ...

The Phase IIa trial is a randomized, placebo-controlled study evaluating the safety, tolerability, and preliminary clinical signals of ONP-002 in patients presenting with acute concussion and mild ...